CIK: 0001637359 · Show all filings
Period: Q2 2025 (← Previous) (Next →)
Filing Date: Aug 14, 2025
Total Value ($000): $154,437 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| BBNX | Beta Bionics Inc. | 1,988,287 | $28,949 | 18.7% | $18.64 | -24.1% | Common Stock | 08659B102 |
| KMTS | Kestra Med Technologies Ltd. | 1,645,893 | $27,289 | 17.7% | $22.98 | -5.0% | Common Stock | G52441105 |
| UPB | Upstream Bio Inc. | 2,036,293 | $22,358 | 14.5% | $22.33 | -58.6% | Common Stock | 91678A107 |
| NUVB | Nuvation Bio | 11,042,728 | $21,533 | 13.9% | $11.18 | -81.4% | Common Stock Class A | 67080N101 |
| BCAX | Bicara Therapeutics Inc. | 2,204,650 | $20,481 | 13.3% | $25.50 | -53.3% | Common Stock | 055477103 |
| REPL | Replimune Group | 1,975,203 | $18,350 | 11.9% | $17.40 | -49.9% | Common Stock | 76029N106 |
| LXEO | Lexeo Therapeutics | 1,184,636 | $4,762 | 3.1% | $12.69 | -74.1% | Common Stock | 52886X107 |
| — | Ikena Oncology | 2,249,123 | $3,014 | 2.0% | $28.25 | — | Common Stock | 45175G108 |
| SANA | Sana Biotechnology, Inc. | 843,750 | $2,303 | 1.5% | $32.56 | -93.7% | Common Stock | 799566104 |
| ALMS | Alumis Inc. | 653,223 | $1,960 | 1.3% | $13.30 | -64.5% | Common Stock | 022307102 |
| ENGN | enGene Holdings Inc. | 526,357 | $1,916 | 1.2% | $10.40 | -63.9% | Common Stock | 29286M105 |
| IMUX | Immunic Inc. | 1,788,160 | $1,248 | 0.8% | $13.89 | -93.4% | Common Stock | 4525EP101 |
| ENGNW | enGene Holdings Inc. | 321,502 | $273 | 0.2% | $0.85 | — | Warrant | 29286M113 |